FindTrial
Sign In

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis - Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000060139
Enrollment
20000
Registered
2025-12-19
Start date
2025-11-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Syncytial Virus Infection

Interventions

None listed

Sponsors

Saga University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) participants younger than 2 years of age; (2) evaluation of mAb prophylaxis for RSV, (3) with placebo or standard care in control group of RCT study design.

Exclusion criteria

Exclusion criteria: (1) included fewer than 10 participants in any study arm; (2) represented subgroup or post hoc analyses of previously published trials; or (3) studies focused on discontinued medicine such as motavizumab or suptavumab.

Design outcomes

Primary

MeasureTime frame
Medically Attended RSV-associated LRTI, RSV-associated hospitalization, Severe Medically Attended RSV-associated LRTI, treatment-associated adverse events—

Countries

Japan,Asia(except Japan),North America,South America,Australia,Europe,Africa

Contacts

Public ContactYUMENG ZHANG

Faculty of Medicine, Saga University, Saga, Japan Department of Pediatrics

octopus.emily@gmail.com09094328800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026